BGM Group (BGM) vs Genelux (GNLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Genelux (GNLX) has outperformed BGM Group (BGM) over the past year, losing 56.3% versus a loss of 96.7%. BGM Group is the larger company by market cap ($108.6 million vs $103.4 million), about 1.1 times the size. BGM Group converts more of its revenue into profit, with a net margin of -52.6% versus -401812.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGM | GNLX |
|---|---|---|
| Share price | $8.13 | $2.17 |
| Market cap | $108.57M | $103.36M |
| 1-day change | 0.00% | -4.82% |
| YTD return | -92.77% | -50.23% |
| 1-year return | -96.73% | -56.25% |
| 5-year return | -98.31% | — |
| EPS (TTM) | $-4.80 | $-0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $37.92M | $8.00K |
| Revenue growth (YoY) | +51.09% | 0.00% |
| Net income (latest FY) | $-19.94M | $-32.15M |
| Gross margin | 16.64% | — |
| Operating margin | -33.18% | -415175.00% |
| Net margin | -52.59% | -401812.50% |
| 52-week high | $263.70 | $5.89 |
| 52-week low | $0.00 | $1.77 |
| Distance from 52-week high | -96.92% | -63.16% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +767.74% |
| Average volume | 6.18K | 333.31K |
| Shares outstanding | 12.69M | 47.63M |
| Employees | — | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GNLX has outperformed BGM by 40.5 percentage points over the past year.
- BGM Group is more profitable, keeping -52.6 cents of every revenue dollar as net income versus -401812.5 cents for Genelux.
- BGM Group grew revenue faster in its latest fiscal year (+51.09% vs 0.00%).
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
BGM vs GNLX FAQ
Which is bigger, BGM Group or Genelux?
BGM Group (BGM) is larger, with a market capitalization of $108.57M compared with $103.36M for Genelux (GNLX).
Which stock has performed better over the past year, BGM or GNLX?
GNLX returned -56.25% over the past 12 months, compared with -96.73% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are BGM Group and Genelux in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.